A clinical trial of a gene-editing technique on advanced lung cancer patients in China has aroused world attention in medical circles. The potentially revolutionary CRISPR-Cas9 technique allows scientists to selectively edit genome parts and replace them with new DNA stretches in the hope that cert
```
Members Only

Login or create an account to continue

This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.

New to BusinessDay? Register now and start reading.

```

Nigeria's leading finance and market intelligence news report. Also home to expert opinion and commentary on politics, sports, lifestyle, and more

Join BusinessDay whatsapp Channel, to stay up to date

Open In Whatsapp